Autopsy report · NCT05649202

Hepatitis C in Prison: Study of Screening and Rapid Treatment (HEPAPRIS)

“No patient eligible”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Sponsor

Assistance Publique - Hôpitaux de Paris

Sponsor type

University, hospital or other

Conditions

Chronic HIV Infection

Interventions

Xpert® HCV Viral test; FibroScan® test

Participants

0

Sites

1

Countries

France

Trials that died the same way

• The Efficacy and Safety of Alemtuzumab in Auotoimmune Cytopenias
  “no eligible patient” (98% match in meaning)
• The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study
  “Lack of eligible patients” (84% match in meaning)
• Endothelial Protection in Convalescent COVID-19 Patients
  “Lack of the eligible patients” (83% match in meaning)
• Non-alcoholic Fatty Liver Disease (NAFLD) in HIV: The Role of Nutritional Interventions
  “Not enough eligible patients available” (82% match in meaning)
• The Effect of Probiotics on Response to Therapy and on Adverse Effect in Patients Treated With Colchicine for Familial Mediterranean Fever.
  “no patient enroled” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.